Building better therapy for children with acute lymphoblastic leukemia

William L. Carroll, Elizabeth A. Raetz

Research output: Contribution to journalShort surveypeer-review

5 Scopus citations


Childhood acute lymphoblastic leukemia is one of the most curable of all human cancers, but new approaches are urgently needed for children who relapse and to avoid severe side effects of curative therapy. Work from the laboratories of Rob Pieters and William Evans, including a paper in this issue of Cancer Cell, has led to the identification of genes whose expression correlates with drug crossresistance and long term outcome. The goal is now to integrate these and other findings using gene expression technology into the care of children with the most common pediatric malignancy.

Original languageEnglish
Pages (from-to)289-291
Number of pages3
JournalCancer Cell
Issue number4
StatePublished - Apr 2005
Externally publishedYes


Dive into the research topics of 'Building better therapy for children with acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this